CVR: 39788705
Previous names: Ankrin Therapeutics IvS
Ankrin Therapeutics ApS was a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2018. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Ankrin Therapeutics IvS. In 2023, the company reported a gross profit of DKK -497,960 and a net result of DKK -2,334,458 compared with DKK -2,732,702 the year before. Equity amounted to DKK -6,779,478.
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringCompared to 1.052 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Ankrin Therapeutics ApS was dissolved on January 22, 2026.
As of February 25, 2025, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has stepped down as auditor of Ankrin Therapeutics ApS.
As of February 25, 2025, Ulrik Svane Sørensen has left the board of directors of Ankrin Therapeutics ApS.
As of February 25, 2025, Anja Groth has left the board of directors of Ankrin Therapeutics ApS.
As of February 25, 2025, Ulrik Svane Sørensen has stepped down as adm. dir. of Ankrin Therapeutics ApS.
As of February 25, 2025, Thomas Michael Frimurer has stepped down as director of Ankrin Therapeutics ApS.
As of February 25, 2025, Anja Groth has stepped down as director of Ankrin Therapeutics ApS.
As of February 25, 2025, Jimmy Arnold Van heusden has stepped down as chairman of Ankrin Therapeutics ApS.
Ankrin Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -497,960, and the net result was DKK -2,334,458.
Ankrin Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -1,024,945, and the net result was DKK -2,732,702.
Ankrin Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -2,427,405, and the net result was DKK -4,493,439.
Ankrin Therapeutics ApS has published its annual report for 2020. Gross profit came to DKK -2,066,728, and the net result was DKK -3,485,420.
As of February 15, 2021, Ulrik Svane Sørensen has joined the board of directors of Ankrin Therapeutics ApS.
As of February 15, 2021, Thomas Michael Frimurer has left the board of directors of Ankrin Therapeutics ApS.
As of February 15, 2021, Jimmy Arnold Van heusden is registered as chairman of Ankrin Therapeutics ApS.
As of February 14, 2021, Ulrik Svane Sørensen has stepped down as chairman of Ankrin Therapeutics ApS.
As of September 14, 2020, Thomas Michael Frimurer has joined the board of directors of Ankrin Therapeutics ApS.
As of September 14, 2020, Anja Groth has joined the board of directors of Ankrin Therapeutics ApS.
As of September 14, 2020, Ulrik Svane Sørensen is registered as chairman of Ankrin Therapeutics ApS.
On September 14, 2020, the company changed its name from Ankrin Therapeutics IvS to Ankrin Therapeutics ApS.
Ankrin Therapeutics ApS has published its interim report for the period August 16, 2018 – December 31, 2019.
As of January 31, 2020, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has been appointed auditor of Ankrin Therapeutics ApS.
As of January 28, 2019, Ulrik Svane Sørensen is registered as adm. dir. of Ankrin Therapeutics ApS.
As of August 16, 2018, Thomas Michael Frimurer is registered as director of Ankrin Therapeutics ApS.
As of August 16, 2018, Anja Groth is registered as director of Ankrin Therapeutics ApS.
Ankrin Therapeutics ApS was founded on August 16, 2018.
Companies in the same industry and area
CVR 40766383
CVR 46613139
CVR 34688605
CVR 44504332
CVR 43917897
companydata.dk